NON RARE IN EUROPE: Tourette syndrome

Tourette syndrome (TS), also known as Gilles de la Tourette syndrome or Tourette disorder, is a neurodevelopmental condition characterized by multiple motor tics and at least one vocal (phonic) tic that persist for more than one year. Tics are sudden, rapid, recurrent, nonrhythmic movements or vocalizations that typically begin in childhood, most commonly between ages 4 and 6. Motor tics often start in the face and head region (such as eye blinking, facial grimacing, or head jerking) and may progress to involve other body parts. Vocal tics can range from simple sounds like throat clearing, sniffing, or grunting to more complex vocalizations. Coprolalia (involuntary utterance of obscene words), though widely associated with the condition in popular culture, occurs in only a minority of patients (approximately 10-15%). Tourette syndrome primarily affects the nervous system, specifically involving dysfunction in cortico-striato-thalamo-cortical circuits of the brain. The condition frequently co-occurs with other neurobehavioral disorders, most notably attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD), which may cause more functional impairment than the tics themselves. Other common comorbidities include anxiety disorders, learning difficulties, and behavioral problems. Tic severity typically peaks during early adolescence and often improves significantly by late adolescence or early adulthood, though some individuals continue to experience tics throughout their lives. Treatment is individualized and is generally recommended when tics cause significant distress or functional impairment. Behavioral therapies, particularly Comprehensive Behavioral Intervention for Tics (CBIT) and habit reversal training, are considered first-line treatments. Pharmacological options include alpha-2 adrenergic agonists (clonidine, guanfacine), antipsychotic medications (such as aripiprazole, risperidone, and haloperidol), and medications targeting comorbid conditions. Deep brain stimulation (DBS) is being investigated for severe, treatment-refractory cases. There is currently no cure for Tourette syndrome, but many patients experience substantial improvement with appropriate management.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about NON RARE IN EUROPE: Tourette syndrome